We aimed to characterize the association between baseline BMI and 12-month outcomes after PCI for myocardial infarction in a large, unselected national cohort and to explore how this relationship interacts with contemporary P2Y12 inhibitor therapy. The gene discussed is P2RY12; the disease is myocardial infarction.